Skip to main content
Erschienen in: Esophagus 4/2012

01.12.2012 | Original Article

Prevalence and trends of malignant and benign esophageal lesions in Iran between 1997 and 2007

verfasst von: Shokouh Taghipour-zahir, Fariba Binesh, Naeemeh Sadat Mosavi

Erschienen in: Esophagus | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Esophageal cancer is one of the most common malignancies with high mortality worldwide. It comprises two major subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevalence of each subtype varies substantially in different geographic regions. In Iran and China, for instance, squamous cell carcinoma predominates. Most Iranian studies regarding benign and malignant lesions of the esophagus to date have focused on the northern part of the country, and a knowledge gap exists regarding the prevalence of esophageal lesions in other parts of the country.

Methods

To assess the prevalence and frequency of benign and malignant esophageal lesions, clinical history of patients who underwent upper gastrointestinal endoscopy and biopsy between 1997 and 2007 in Yazd, Iran was reviewed.

Results

Among 294 malignant lesions, squamous cell carcinoma was the most frequent subtype (70.06 %), followed by adenocarcinoma (29.25 %). Of the 387 benign lesions, most frequent diagnoses were reflux esophagitis 215 (55.5 %), esophagus ulcer 91 (23.51 %), and Barrett’s esophagus 73 (18.86 %). During the 11-year study period, incidence of adenocarcinoma gradually increased over time. On the other hand, squamous cell carcinoma incidence and total incidence of esophageal malignancies did not show a significant trend over time.

Conclusions

Squamous cell carcinoma remains the most common subtype of esophagus malignancies in Yazd, Iran, although an increasing trend towards adenocarcinoma is also evident.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
Zurück zum Zitat Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
4.
Zurück zum Zitat Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMedCrossRef
5.
Zurück zum Zitat Tran GD, Sun X-D, Abnet CC, Fan J-H, Dawsey SM, Dong Z-W, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.PubMedCrossRef Tran GD, Sun X-D, Abnet CC, Fan J-H, Dawsey SM, Dong Z-W, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–63.PubMedCrossRef
6.
Zurück zum Zitat Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.PubMedCrossRef Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.PubMedCrossRef
7.
Zurück zum Zitat Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.PubMedCrossRef Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.PubMedCrossRef
8.
Zurück zum Zitat Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.PubMedCrossRef Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.PubMedCrossRef
9.
Zurück zum Zitat Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–13.PubMedCrossRef Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–13.PubMedCrossRef
10.
Zurück zum Zitat Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology. 1984;87:927–33.PubMed Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk? Gastroenterology. 1984;87:927–33.PubMed
11.
Zurück zum Zitat Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.PubMedCrossRef Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.PubMedCrossRef
12.
Zurück zum Zitat Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett’s esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212–6.PubMedCrossRef Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett’s esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212–6.PubMedCrossRef
13.
Zurück zum Zitat Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–97.PubMedCrossRef
14.
Zurück zum Zitat Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran—a review. Eur J Cancer. 2009;45:3156–65.PubMedCrossRef Islami F, Kamangar F, Nasrollahzadeh D, Moller H, Boffetta P, Malekzadeh R. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran—a review. Eur J Cancer. 2009;45:3156–65.PubMedCrossRef
15.
Zurück zum Zitat Taghavi N, Nasrollahzadeh D, Merat S, Yazdanbod A, Hormazdi M, Sotoudeh M, et al. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World J Gastroenterol. 2007;13:5367–70.PubMed Taghavi N, Nasrollahzadeh D, Merat S, Yazdanbod A, Hormazdi M, Sotoudeh M, et al. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World J Gastroenterol. 2007;13:5367–70.PubMed
16.
Zurück zum Zitat Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7:375–80.PubMed Mosavi-Jarrahi A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev. 2006;7:375–80.PubMed
17.
Zurück zum Zitat Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113–8.PubMedCrossRef Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113–8.PubMedCrossRef
18.
Zurück zum Zitat Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004;57:37–42.PubMedCrossRef Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004;57:37–42.PubMedCrossRef
19.
Zurück zum Zitat Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–34.PubMed Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–34.PubMed
20.
Zurück zum Zitat Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126:903–13.PubMedCrossRef Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004;126:903–13.PubMedCrossRef
21.
Zurück zum Zitat Wallerstein C. Costa Rica tackles high rates of stomach cancer. BMJ. 2001;323:1270.CrossRef Wallerstein C. Costa Rica tackles high rates of stomach cancer. BMJ. 2001;323:1270.CrossRef
22.
Zurück zum Zitat Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer. 1973;28:197–214.PubMedCrossRef Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer. 1973;28:197–214.PubMedCrossRef
23.
Zurück zum Zitat Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10:70–82.PubMed Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007;10:70–82.PubMed
24.
Zurück zum Zitat Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer. 2004;90:1402–6.PubMedCrossRef Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer. 2004;90:1402–6.PubMedCrossRef
25.
Zurück zum Zitat Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63.PubMedCrossRef Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer. 2008;98:1857–63.PubMedCrossRef
26.
Zurück zum Zitat Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case–control study. BMJ. 2009;338:b929.PubMedCrossRef Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case–control study. BMJ. 2009;338:b929.PubMedCrossRef
27.
Zurück zum Zitat Nasseri-Moghaddam S, Malekzadeh R, Sotoudeh M, Tavangar M, Azimi K, Sohrabpour A–A, et al. Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol. 2003;18:315–21.PubMedCrossRef Nasseri-Moghaddam S, Malekzadeh R, Sotoudeh M, Tavangar M, Azimi K, Sohrabpour A–A, et al. Lower esophagus in dyspeptic Iranian patients: a prospective study. J Gastroenterol Hepatol. 2003;18:315–21.PubMedCrossRef
28.
Zurück zum Zitat Polednak AP. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef Polednak AP. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98–100.PubMedCrossRef
29.
Zurück zum Zitat Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53.PubMedCrossRef Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53.PubMedCrossRef
30.
Zurück zum Zitat Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012.
31.
Zurück zum Zitat Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–54.PubMedCrossRef Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–54.PubMedCrossRef
32.
Zurück zum Zitat Lu C-L, Lang H-C, Luo J-C, Liu C-C, Lin H-C, Chang F-Y, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269–74.PubMedCrossRef Lu C-L, Lang H-C, Luo J-C, Liu C-C, Lin H-C, Chang F-Y, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269–74.PubMedCrossRef
33.
Zurück zum Zitat Melhado RE, Alderson D, Tucker O. The changing face of esophageal cancer. Cancers. 2010;2:1379–404.CrossRef Melhado RE, Alderson D, Tucker O. The changing face of esophageal cancer. Cancers. 2010;2:1379–404.CrossRef
34.
Zurück zum Zitat Hongo M. Review article: Barrett’s oesophagus and carcinoma in Japan. Aliment Pharmacol Ther. 2004;20:50–4.PubMedCrossRef Hongo M. Review article: Barrett’s oesophagus and carcinoma in Japan. Aliment Pharmacol Ther. 2004;20:50–4.PubMedCrossRef
35.
Zurück zum Zitat Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. In: Schneider PM, editor. Adenocarcinoma of the esophagogastric junction. Springer, Berlin; 2010. p. 1–17. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. In: Schneider PM, editor. Adenocarcinoma of the esophagogastric junction. Springer, Berlin; 2010. p. 1–17.
36.
Zurück zum Zitat Foroutan M, Norouzi A, Molaei M, Mirbagheri S, Irvani S, Sadeghi A, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig Dis Sci. 2010;55:28–31.PubMedCrossRef Foroutan M, Norouzi A, Molaei M, Mirbagheri S, Irvani S, Sadeghi A, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig Dis Sci. 2010;55:28–31.PubMedCrossRef
37.
Zurück zum Zitat Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–72.PubMedCrossRef Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg. 2000;190:562–72.PubMedCrossRef
38.
Zurück zum Zitat McFadden DW, Rudnicki M, Talamini MA. Primary small cell carcinoma of the esophagus. Ann Thorac Surg. 1989;47:477–80.PubMedCrossRef McFadden DW, Rudnicki M, Talamini MA. Primary small cell carcinoma of the esophagus. Ann Thorac Surg. 1989;47:477–80.PubMedCrossRef
39.
Zurück zum Zitat Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–9.PubMedCrossRef
40.
Zurück zum Zitat Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer. 1988;61:612–7.PubMedCrossRef Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer. 1988;61:612–7.PubMedCrossRef
Metadaten
Titel
Prevalence and trends of malignant and benign esophageal lesions in Iran between 1997 and 2007
verfasst von
Shokouh Taghipour-zahir
Fariba Binesh
Naeemeh Sadat Mosavi
Publikationsdatum
01.12.2012
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 4/2012
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-012-0343-7

Weitere Artikel der Ausgabe 4/2012

Esophagus 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.